Soleus Capital Management’s Dyne Therapeutics DYN Stock Holding History

Soleus Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$196K	–	101
2025 Q4	$196K	Buy	+10,000	New	+$189K	0.01%	93
2024 Q4	–	Sell	-117,500	Closed	-$4.22M	–	91
2024 Q3	$4.22M	Sell	117,500 -83,500	-42%	-$3.32M	0.33%	64
2024 Q2	$7.09M	Buy	+201,000	New	+$5.84M	0.63%	50
2022 Q1	–	Sell	-338,760	Closed	-$4.03M	–	73
2021 Q4	$4.03M	Buy	338,760 +160,400	+90%	+$2.25M	0.4%	43
2021 Q3	$2.9M	Hold	178,360	–	–	0.45%	55
2021 Q2	$3.75M	Buy	178,360 +4,000	+2%	+$75.2K	0.58%	37
2021 Q1	$2.71M	Buy	+174,360	New	+$3.37M	0.49%	42

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Soleus Capital Management's DYN Position: Q1 2026 in Review

Soleus Capital Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 10,000 shares — an estimated $196K sold.

Soleus Capital Management first reported a position in DYN in Q1 2021 and held it in 7 quarters. The position peaked at $7.09M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Soleus Capital Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
Soleus Capital Management sold 10,000 Dyne Therapeutics shares in Q1 2026, an estimated $196K.
Soleus Capital Management first reported a position in Dyne Therapeutics in Q1 2021 and held it in 7 quarters.
Soleus Capital Management's Dyne Therapeutics position peaked at $7.09M in Q2 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.